Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
Q4 2024 Biogen Inc Earnings Call
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...
Biogen price target lowered to $245 from $281 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...
Biogen (BIIB) Q4 2024 Earnings Call Transcript
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...
Biogen price target lowered to $144 from $175 at Stifel
Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...
Alcami Appoints Tori E. Arens as President, Drug Product
Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the ...
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...